{"title":"[早期乳腺癌辅助 S-1 加内分泌治疗--两个病例的报告]。","authors":"Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1065-1067"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases].\",\"authors\":\"Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"51 10\",\"pages\":\"1065-1067\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases].
We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.